Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Troglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 8/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | MPC2 | O95563 | 2/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Troglitazone SCHEMBL12496814 | 1.00 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL30050392 | 1.00 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL8496660 | 1.00 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL29349864 | 1.00 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL1536757 | 1.00 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL5672808 | 1.00 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL21630 | 1.00 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL15888838 | 1.00 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL5672813 | 1.00 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL3050513 | 0.99 | MEN1 (0.63) | MEN1MAPTKMT2ATDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 42211 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | MADRIGAL PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260048013-A1 | PHARMACEUTICAL FORMULATION WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | CONSEJO SUPERIOR INVESTIGACION (ES) | 2026-02-19 | — | — | US | claimed |
| EP-4684799-A2 | ANTIBODIES THAT DISRUPT THE INTERACTION OF GAL3 AND INSULIN RECEPTOR OR INTEGRINS AND METHODS OF USE THEREOF | TrueBinding, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4683679-A1 | METHOD FOR DIAGNOSING AND TREATING NIS-EXPRESSING CARCINOMAS AND METASTASES | NUSKE, Andreas (DE) | 2026-01-28 | — | — | EP | claimed |
| EP-3452041-B1 | COMPOSITIONS AND METHODS FOR ADMINISTERING PPAR-GAMMA-AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2026-01-14 | — | — | EP | claimed |
| US-12522805-B2 | Method for obtaining cell spheroids | D.I.V.A EXPERTISE (FR) | 2026-01-13 | — | — | US | claimed |
| US-20250360215-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES | YUH CHIOU HWA (US) | 2025-11-27 | — | — | US | claimed |
| US-20250352528-A1 | TOPICAL ROSIGLITAZONE FOR RADIATION-INDUCED SKIN INJURY | BRIGHAM & WOMENS HOSPITAL INC (US) | 2025-11-20 | — | — | US | claimed |
| US-5457109-A | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus | WARNER-LAMBERT COMPANY (US) | 1995-10-10 | — | — | US | claimed |
| CN-2207197-Y | Heating medicinal band for diabetes | XING GUANGMING (CN) | 1995-09-13 | — | — | CN | claimed |
| WO-1995007694-A1 | USE OF THIAZOLIDINEDIONES TO PREVENT OR DELAY ONSET OF NIDDM | SANKYO COMPANY, LIMITED (JP) | 1995-03-23 | — | — | WO | claimed |
| WO-1995007697-A2 | USE OF THIAZOLIDINEDIONE DERIVATIVES AND RELATED ANTIHYPERGLYCEMIC AGENTS IN THE TREATMENT OF DISEASE STATES AT RISK FOR PROGRESSING TO NONINSULIN-DEPENDENT DIABETES MELLITUS | WARNER-LAMBERT COMPANY (US) | 1995-03-23 | — | — | WO | claimed |
| EP-0439321-B1 | Thiazolidine derivatives having anti-hypertensive activity and their therapeutic use | SANKYO CO (JP) | 1995-03-15 | — | — | EP | claimed |
| EP-0617612-A1 | A PROCESS FOR THE PREPARATION OF A SOLID DISPERSION. | WARNER LAMBERT CO (US) | 1994-10-05 | — | — | EP | claimed |
| WO-1993011749-A1 | A PROCESS FOR THE PREPARATION OF A SOLID DISPERSION | WARNER-LAMBERT COMPANY (US) | 1993-06-24 | — | — | WO | claimed |
| EP-0139421-B1 | THIAZOLIDINE DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SANKYO COMPANY LIMITED (JP) | 1988-04-27 | — | — | EP | claimed |
| US-4572912-A | Thiazolidine derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1986-02-25 | — | — | US | claimed |
| EP-0139421-A1 | Thiazolidine derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1985-05-02 | — | — | EP | claimed |